Image source: Shutterstock

Highlights

  • Sanofi agrees to acquire Vigil Neuroscience for $8 per share plus contingent value rights potentially worth $2 per share.
  • Acquisition aims to advance the development of VG-3927, a therapy targeting microglial TREM2 activation for neurodegenerative diseases.
  • Deal expected to close in Q3 2025, pending regulatory and shareholder approvals.

Sanofi (NASDAQ: SNY) is a global healthcare company focused on developing medicines and vaccines, with an emphasis on innovation, sustainability, and social responsibility. They company has announced a definitive agreement to acquire Vigil Neuroscience, Inc. (NASDAQ: VIGL), a clinical-stage biotechnology company focused on treatments for neurodegenerative diseases.

Under the terms of the deal, Sanofi will pay $8.00 per share in cash upfront to Vigil shareholders. Additionally, shareholders will receive a non-tradeable contingent value right (CVR) that may provide an extra $2.00 per share if Vigil’s lead therapy, VG-3927, achieves its first commercial sale within a specified timeframe. The total equity value of the transaction, including the CVR, is approximately $600 million on a fully diluted basis.

VG-3927 is a small molecule designed to activate TREM2, a receptor involved in regulating microglial function. Microglia are immune cells in the central nervous system that, when properly activated, help clear cellular debris and reduce inflammation. In Alzheimer’s disease and other neurodegenerative conditions, microglial function is impaired, leading to neural damage. Activation of TREM2 is believed to enhance microglial activity, potentially slowing disease progression.

Currently approved treatments for Alzheimer’s disease do not halt or reverse the illness, and patient eligibility for these therapies is often limited. The development of new therapies like VG-3927 aims to address these unmet medical needs by offering potentially safer and more effective treatment options.

As part of the acquisition, Vigil’s monoclonal antibody program, Iluzanebart (VGL101), will not be included in the deal. The rights to this program will revert to its original licensor, Amgen, and the exclusive license agreement between Vigil and Amgen for VGL101 will be terminated before the transaction closes.

Certain key stakeholders, including Atlas Ventures and Vigil’s CEO, Ivana Magovcevic-Liebisch, have entered into voting agreements supporting the transaction, representing approximately 16% of Vigil’s outstanding shares.

The closing of the acquisition is subject to customary conditions, including approval by most Vigil shareholders, regulatory clearance under the Hart-Scott-Rodino Antitrust Improvements Act, and other typical closing requirements. Sanofi and Vigil anticipate completing the transaction in the third quarter of 2025.